Madrigal Pharmaceuticals Inc (MDGL)

[DMOST]

3 Top Stocks for Investing in Pharma's Next $35 Billion Market

Madrigal Pharmaceuticals: Fast climber

This biotech came out of nowhere to take a leading position in the NASH dash with solid data for MGL-3196 late last year. The company followed up in May with results that suggest it will give Ocaliva a challenge. During a mid-stage study, 27% of patients treated with MGL-3196 achieved NASH resolution versus just 6% of those treated with a placebo.

Intercept is months away from wrapping up Ocaliva's pivotal NASH trial, but Madrigal hasn't even started one yet. When Madrigal checked in last, management was still waiting for the FDA to sign off on the company's pivotal trial design.

At recent prices Madrigal sports a $3.5 billion market cap that could soar in the long run if MGL-3196 repeats previous observations without any safety issues, but investors need to understand that it could also come crashing down if there's any trouble with its lead candidate. There's nothing in the company's pipeline to fall back on.

Mid-stage results left no doubt that MGL-3196 lowers liver fat content for patients, but we still don't know a lot about the drug's safety profile. No troubling safety issues reared their ugly heads during the mid-stage study that propelled Madrigal into the spotlight, but there were only 107 patients in the trial.
https://finance.yahoo.com/news/3-top-stocks-investing-pharma-131700454.html

GO MDGL

"PEACE"

[stocktrademan]

MDGL buy 243.92























normal chart




log chart

[DMOST]

Is Viking Therapeutics, Inc. a Buy?

Viking Therapeutics, Inc. (NASDAQ: VKTX) is losing money like it's going out of style. The biotech's total revenue this year matches its total revenue last year -- zip, zero, nada. At best, Viking is still several years away from even possibly winning approval for its first drug.

So if you ask me whether or not Viking Therapeutics stock is a buy, my answer is an enthusiastic... "yes."

That's my answer, at least, for aggressive investors. Despite all of the negatives that I ticked off for Viking, I really like this stock as a speculative play.

Similar drugs, very different valuations

The biggest reason why I think so highly of Viking Therapeutics' prospects is that I also think highly of Madrigal Pharmaceuticals' (NASDAQ: MDGL) prospects. In May, Madrigal announced really good results from a phase 2 clinical study of its lead candidate MGL-3196 in treating non-alcoholic steatohepatitis (NASH).

MGL-3196 met its primary endpoint of a statistically significant reduction of liver fat. Researchers use the probability value, or p-value, to determine whether a result was statistically significant. A p-value of less than 0.05 is the standard threshold they seek. MGL-3196 achieved a p-value of less than 0.0001. As icing on the cake, the drug also hit all of the study's key secondary endpoints. And it did all of this with a pretty good safety profile.

What does all of this have to do with Viking? The biotech also has a pipeline candidate, VK2809, that's still in a phase 2 clinical study targeting treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL cholesterol. NASH, by the way, is a serious type of NAFLD. Here's the important thing to know: Both MGL-3196 and VK2809 are thyroid hormone receptor (THR) beta-selective agonists.

Now, it's possible that Viking's drug won't be as effective as Madrigal's. However, I think there's a pretty good chance that VK2809 will be successful in its phase 2 study. We won't know for sure, though, until Viking announces the results from the study later this year.

In the meantime, Madrigal claims a market cap of $3.7 billion compared to Viking's market cap of around $640 million. The difference in the two biotechs' valuations is big primarily because of the possibility that VK2809's results will be disappointing. But if Viking reports positive results for the drug in a few months, the gap between its market cap and Madrigal's will narrow significantly.
An attractive acquisition target

In June, I listed Madrigal and Viking as the two top takeover targets in the NASH space. I still think both biotechs are likely to be on the radar screens for bigger players.

I'm actually rooting for Gilead Sciences (NASDAQ: GILD) to buy either Madrigal or Viking and for Pfizer (NYSE: PFE) to scoop up whichever one Gilead doesn't acquire. Why? I own positions in both Gilead and Pfizer and would love to see them succeed in the NASH market.

Gilead would be a great suitor for Viking for a couple of reasons. First, the big biotech is already a leader in NASH with three candidates in its pipeline. Based on what I've read and heard from scientists who are experts in NASH, I suspect that combination therapies will be most effective in treating the disease. Adding a THR beta-selective agonist in the mix with its ASK-1 inhibitor, ACC inhibitor, and FXR agonist could be just the ticket for Gilead to become a major winner in the NASH market.

The second reason I think Gilead is an ideal company to buy Viking is that it has plenty of money to spend. As of the end of June, Gilead claimed $31.7 billion in cash, cash equivalents, and marketable securities. It could buy Viking with its spare change.

Pfizer isn't quite as far along as Gilead is. The big pharma company has a couple of NASH candidates in phase 2 testing with another experimental drug in phase 1. None of these drugs have the same mechanism of action as VK2809, so Viking's drug could be a good addition to Pfizer's pipeline. Pfizer isn't hurting for cash to spend on a small acquisition, either, with the company reporting $13.4 billion in cash, cash equivalents, and short-term investments as of the end of June.
Adding it all up

As I pointed out, there are plenty of reasons to avoid Viking Therapeutics stock. However, I think the risk-reward proposition for the stock looks pretty good.

All Viking needs is successful results in its phase 2 study of VK2809. Based on historical data, there's a 45% probability that a metabolic drug in phase 2 testing will have positive results and advance to a phase 3 clinical study. I think the previous results for Madrigal's similar drug gives VK2809 even better odds than that.

If I'm right and Viking announces solid phase 2 results in a few months, the biotech's share price will soar. And I suspect that one or more big players looking to pick up a promising NASH candidate will come calling. Aggressive investors should like those prospects.
https://finance.yahoo.com/news/viking-therapeutics-inc-buy-130200243.html

GO MDGL

"PEACE"

[DMOST]

Madrigal Pharmaceuticals Inc (MDGL)

Been trending down nearly 14 consecutive days in a row sense July?

Best guess is some longs have been selling, taking profits after they've been holding for a year.

Capital gains taxes are less on the profits.........Many still buying the dips though.

GO MDGL

"PEACE"

[DMOST]

Madrigal (MDGL) Posts Narrower than Expected Loss in Q2

West Conshohocken, Pennsylvania based Madrigal Pharmaceuticals, Inc. MDGL is developing small molecule drugs to treat cardiovascular, metabolic, and liver diseases. The company’s lead pipeline candidate- MGL-3196, is being evaluated for non-alcoholic steatohepatitis (“NASH”), a liver disease. The company is also evaluating the candidate for the treatment of heterozygous familial hypercholesterolemia (“HeFH”)

Madrigal’s earnings track record has been decent so far with a four-quarter average positive earnings surprise of 20.17%. The company beat estimates thrice in the four trailing quarters. Estimates have remained stable over the past one month.

Currently, Madrigal has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Madrigal reported a loss of 45 cents in the second quarter of 2018 which was narrower than the Zacks Consensus Estimate of loss of 56 cents.

Revenues: The company did not report any revenue in the reported quarter.Research and Development (R&D) expenses decreased 25% year over year to $5.1 million. General and administrative expenses increased 68.8% year over year to $2.7 million.

Share Market Activity: There was no movement in share price in pre-market trading.

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
https://finance.yahoo.com/news/madrigal-mdgl-posts-narrower-expected-142202142.html

GO MDGL

"PEACE"

[DMOST]

Madrigal: 2Q Earnings Snapshot

WEST CONSHOHOCKEN, Pa. (AP) _ Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported a loss of $6.5 million in its second quarter.

On a per-share basis, the West Conshohocken, Pennsylvania-based company said it had a loss of 45 cents.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 56 cents per share.

Madrigal shares have more than doubled since the beginning of the year. The stock has risen fifteenfold in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stoc

https://finance.yahoo.com/news/madrigal-2q-earnings-snapshot-110158778.html

GO MDGL

"PEACE"

[DMOST]

Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
GlobeNewswire•August 7, 2018

CONSHOHOCKEN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL) today announced its second quarter 2018 financial results and described recent clinical and corporate accomplishments including:

Positive Phase 2 Clinical Results - MGL-3196 demonstrated highly statistically significant results for the key 36-week endpoints in its Phase 2 clinical trial in non-alcoholic steatohepatitis (NASH), including statistically significant reductions of liver fat and resolution of NASH
Madrigal’s abstract "In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy" has been selected for oral presentation at The Liver Meeting® 2018 in San Francisco. The presentation will take place on Monday, November 12, 2018, at 8:15 AM during the Presidential Plenary – Clinical Science
Increased Capital Position – Madrigal completed an underwritten registered public offering in which the gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $329 million
Progress in out-licensed legacy oncology programs – Madrigal’s licensee for its Hsp90 inhibitor program, Aldeyra Therapeutics, Inc., recently announced that, ADX-1612, its lead Hsp90 compound, is being advanced in multiple indications: mesothelioma, ovarian cancer and lymphoproliferative immune disease

“We believe the 36-week data from our recently completed Phase 2 clinical study of MGL-3196 in patients with NASH suggest a high likelihood of success in a similarly designed Phase 3 study, for which we are actively preparing, pending regulatory agreement,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “With our financial raise completed, which provided more than $300 million of additional capital, we are in a strong position to expedite the MGL-3196 development program in NASH and dyslipidemias.”

Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal added, “We believe the totality of data from our clinical and preclinical studies to date, including the consistency of the various parameters related to clinical benefits and safety, demonstrate the potential of MGL-3196 to resolve NASH and improve multiple atherogenic lipids. We are pleased our abstract was selected by AASLD as an oral presentation in the presidential plenary clinical session and look forward to presenting these encouraging clinical outcomes in November at The Liver Meeting® 2018.”

Financial Results for the Three Months and Six Months Ended June 30, 2018

As of June 30, 2018, Madrigal had cash, cash equivalents and marketable securities of $490.3 million, compared to $191.5 million at December 31, 2017. The increase in cash and marketable securities resulted primarily from the net proceeds of $311.8 million from Madrigal’s public offering of common stock in June 2018, partially offset by cash used in operations of $14.0 million.

Operating expenses were $7.8 million and $14.9 million, respectively, for the three month and six month periods ended June 30, 2018, compared to $8.4 million and $14.5 million in the comparable prior year periods.

Research and development expenses for the three month and six month periods ended June 30, 2018 were $5.1 million and $10.3 million, respectively, as compared to $6.8 million and $11.2 million in the comparable prior year periods. The decreases are primarily attributable to completion of treatment in our Phase 2 clinical studies in 2018.

General and administrative expenses for the three month and six month periods ended June 30, 2018 were $2.7 million and $4.6 million, respectively, as compared to $1.6 million and $3.3 million in the comparable prior year periods. The increases are due primarily to higher non-cash stock compensation expense from stock option awards.

Interest income for the three month and six month periods ended June 30, 2018 was $1.2 million and $1.9 million, respectively, as compared to $92 thousand and $168 thousand in the comparable prior year periods. The change in interest income was due primarily to a higher average principal balance in our investment account in 2018.

Out-Licensed Legacy Oncology Programs

Madrigal’s licensee for its Hsp90 inhibitor program, Aldeyra Therapeutics, Inc., provided a pipeline update during its June 2018 Research Day. ADX-1612 is a novel Hsp90 inhibitor in development for the treatment of post-transplant lymphoproliferative disorder and cancer. Hsp90 is a protein that facilitates cell replication, which is excessive and uncontrolled in certain inflammatory diseases and cancer. ADX-1612 is currently being studied in investigator-sponsored trials for mesothelioma, with clinical results expected in the second half of 2018, and ovarian cancer, with Phase 2 clinical trial initiation expected in the second half of 2018. Aldeyra is further developing ADX-1612 for the treatment of lymphoproliferative immune disease, with Phase 2 clinical testing expected to start in 2019.

Clinical Program Summaries for MGL-3196

NASH

Non-alcoholic Steatohepatitis (NASH) is a common liver disease in the United States and worldwide, unrelated to alcohol use, that is characterized by a build-up of fat in the liver, inflammation, damage (ballooning) of hepatocytes and increasing fibrosis. Although people with NASH may feel well and often do not know they have the disease, NASH can lead to permanent damage, including cirrhosis and impaired liver function in a high percentage of patients.

In October 2016, the first patient was treated in the ongoing Phase 2 trial of MGL-3196 for the treatment of NASH. The randomized, double-blind, placebo-controlled, multi-center Phase 2 study enrolled 125 patients 18 years of age and older with liver biopsy-confirmed NASH and included approximately 25 clinical sites in the United States. Patients were randomized to receive either MGL-3196 or placebo in a 2:1 ratio.

The primary endpoint of the study was the reduction of liver fat at 12 weeks compared with baseline (relative change), assessed by MRI-PDFF. Key secondary endpoints at 36 weeks included: reduction in liver fat compared with baseline (relative change), also assessed by MRI-PDFF; a two-point reduction in NAS (NALFD activity score) on biopsy; resolution of NASH on biopsy; and, safety and tolerability based on adverse events and changes in laboratory values.

The primary endpoint of the study at 12 weeks was achieved. Liver fat was reduced by 36.3% in all MGL-3196 treated patients (78) and 42.0% in a pre-specified group of high exposure MGL-3196 treated patients (44/78), as compared with 9.6% median reduction in liver fat in 38 placebo treated patients. These results were statistically significant (p<0.0001) for both MGL-3196 treatment groups. Further, 75% of the high-exposure MGL-3196 treated patients showed liver fat reductions of ≥30%.

At 36 weeks, MGL-3196 achieved multiple key secondary endpoints including a sustained highly significant (p<0.001) reduction in liver fat compared to placebo as measured by MRI-PDFF; mean relative fat reduction for MGL-3196 was 37% versus 8.9% for placebo. MGL-3196 was associated with a greater percentage of subjects with a 2-point improvement in NAS (56% of 73 patients vs 32% of 34 placebo subjects, p=0.02). NASH resolution (NR) was seen in 27% of MGL-3196 compared with 6% of placebo subjects, p=0.02. MGL-3196 patients with ≥ 30% fat reduction on Week 12 MRI-PDFF demonstrated a higher percentage of 2-point improvement in NAS (70%, p=0.001) and NR (39%, p=0.001) compared with placebo, demonstrating a strong relationship between early reduction in liver fat as demonstrated by week 12 MRI-PDFF and NASH improvement on liver biopsy at Week 36. In patients with NASH Resolution, 35% of the MGL-3196 treated patients and no placebo patients had more advanced NASH (baseline NAS ≥5).

At Week 36, MGL-3196 treated patients showed sustained reduction of fibrosis biomarkers. In MGL-3196 patients with NASH resolution, fibrosis also resolved in 50% of patients and was decreased statistically significantly reduced relative to all placebo patients.

There were statistically significant reductions in liver enzymes in MGL-3196 treated patients compared to placebo treated patients; reductions of greater magnitude were achieved with longer duration of MGL-3196 treatment. Statistically significantly more MGL-3196 treated patients than placebo treated patients had normalization of ALT (alanine transaminase).

Similar to week 12, at week 36 there were sustained, statistically significant reductions in low-density lipoprotein cholesterol (LDL-C), triglycerides, ApoB and lipoprotein(a).

MGL-3196 was well tolerated in this trial with mostly mild and a few moderate AEs which were balanced between drug treated and placebo patients. An increase in incidence of mild transient diarrhea in MGL-3196-treated, often a single episode, at the start of treatment. Diarrhea incidence was not increased later in the study.

Based on liver enzyme inclusion criteria, some patients are receiving extended treatment beyond 36 weeks for up to 36 additional weeks. All patients in this extension study will receive MGL-3196 and only non-invasive assessments will be made, including serial MRI-PDFF, safety labs, and circulating biomarkers.

Additional information about the study [NCT02912260] can be obtained at www.ClinicalTrials.gov.

HeFH
Heterozygous familial hypercholesterolemia (HeFH), and a much rarer form called homozygous familial hypercholesterolemia (HoFH), are severe genetic dyslipidemias typically caused by inactivating mutations in the LDL receptor. Both forms of FH lead to early onset cardiovascular disease. HeFH, the most common dominantly inherited disease, is present in up to 1 in 200 people; the disease is found in higher frequencies in certain more genetically homogenous populations. Treatments exist for both HeFH and HoFH but many patients (as many as 40 percent of HeFH patients) are not able to reach their cholesterol (LDL-C) reduction goals on these therapies, reflecting the lifetime burden of cholesterol buildup in their bodies. Based on evidence of impressive LDL cholesterol lowering in Phase 1, and data suggesting that MGL-3196 has a mechanism of action that is different from and complementary to statins, Madrigal initiated a Phase 2 proof-of-concept trial in HeFH in February 2017 and enrolled 116 patients.

In this Phase 2 HeFH trial, patients who were not at their LDL-C goal were randomized in a 2:1 ratio to receive either MGL-3196 or placebo, in addition to their current cholesterol lowering regimen, which included approximately 75% taking high intensity statins (20/40 mg rosuvastatin or 80 mg atorvastatin), and about 2/3 of patients also taking ezetimibe. MGL-3196 treated patients (placebo corrected) achieved highly significant (p< 0.0001) LDL-C lowering of 18.8%, and 21% LDL-C lowering in those on an optimal dose of MGL-3196. LDL-C lowering was 28.5% in MGL-3196 treated compared to placebo in a prespecified group of patients who did not tolerate high intensity statin doses. Highly significant reductions (p<0.0001) relative to placebo were also observed with ApoB, triglycerides (TG) (25-31%), apolipoprotein CIII (Apo CIII) and Lp(a) (25-40%) in all MGL-3196 treated patients and prespecified subgroups, irrespective of statin treatment.

MGL-3196 was well-tolerated with primarily mild and some moderate AEs, the numbers of which were balanced between placebo and drug-treatment groups.

About MGL-3196
Among its many functions in the human body, thyroid hormone, through activation of its beta receptor, plays a central role in controlling lipid metabolism, impacting a range of health parameters from levels of serum cholesterol and triglycerides to the pathological buildup of fat in the liver. Attempts to exploit this pathway for therapeutic purposes in cardio-metabolic and liver diseases have been hampered by the lack of selectivity of older compounds for the thyroid hormone receptor (THR)-ß, chemically-related toxicities and undesirable distribution in the body.

Madrigal recognized that greater selectivity for thyroid hormone receptor (THR)-ß and liver targeting might overcome these challenges and deliver the full therapeutic potential of THR-ß agonism. Madrigal believes that MGL-3196 is the first orally administered, small-molecule, liver- directed, truly ß-selective THR agonist. MGL- 3196 has now demonstrated in two Phase 2 double-blind, placebo-controlled trials in NASH and HeFH the potential for a broad array of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation. Based on evidence of these pleiotropic actions, coupled with an excellent safety profile, Madrigal plans to initiate a Phase 3 clinical program in NASH and dyslipidemias.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist that is currently in Phase 2 development for NASH and HeFH. For more information, visit www.madrigalpharma.com.

Forward-Looking Statements
This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements contain words such as “expect,” “could,” “may,” “will,” “believe,” “estimate,” "continue," "future,” or the negative thereof or comparable terminology and the use of future dates. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's clinical development of MGL-3196, the timing and outcomes of clinical studies of MGL-3196, and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's filings with the U.S. Securities and Exchange Commission for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.
https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-2018-second-105000932.html

GO MDGL

"PEACE"

[DMOST]

Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is positioned to dominate a “blockbuster market,” according to Goldman Sachs. But while the bank believes in the biotech’s longer-term prospects, it sees no near-term catalysts for Madrigal’s stock.

The Rating

Analyst Salveen Richter downgraded Madrigal to Neutral but maintained his $314 price target.

The Thesis

Richter forecasts limited upside to his fundamental discounted cash flow value and anticipates few value-driving catalysts in the near future. However, he maintains high expectations for MGL-3196.

“We continue to view MGL-3196, a once-daily oral thyroid hormone receptor (THR)-beta agonist, as a best-in-class and industry drug for NASH driven by the positive liver and cardiometabolic profile (per the Phase 2 36-week study) and corroborating KOL feedback,” Richter wrote in a note. “Specifically, based on the efficacy/safety profile seen to date with MDGL’s MGL-3196 - our KOLs suggest this would be a first choice as monotherapy.”

He identifies a “clear development path” for MGL-3196 and anticipates New Drug Applications for two indications with global peak sales of $6 billion.

Additionally, given management’s interest in business development activities to commercialize the candidate, Madrigal could eventually drive value with a merger.

“Post the highly impressive MGL-3196 Ph2 36-week liver biopsy data, MDGL is positioned as a leading next-generation NASH player with a best-in-class strategic asset in a blockbuster market where there are currently no approved therapies,” Richter wrote.
https://finance.yahoo.com/news/goldman-sachs-cuts-madrigal-pharma-190549481.html

..And so we sit idle for a minute, drifting, drifting...Unless the decide to accept a buyout offer.

GO MDGL

"PEACE"

Loading so more on the cheap.

[DMOST]

$305 was the set price of shares in the private offering, which did bring dilution to the Outstanding shares. But what about the float?

Obviously the most recent buyers at $305 are not selling, and those are the "Institutions" who have the big bucks that ruled the volume doing that offering.........So who is selling?

Why Madrigal Pharmaceuticals Stock Is Getting Hammered Today

What happened

Madrigal Pharmaceuticals (NASDAQ: MDGL) stock has fallen by as much as 11.1% today on higher-than-normal volume. The culprit?

Madrigal CEO Paul Friedman stated in an interview late last week that the company is entertaining potential takeover offers, but that "no deals are imminent."

Madrigal had reportedly put itself up for sale last month after posting stellar phase 2 results for its experimental nonalcoholic steatohepatitis (NASH) drug MGL-3196. Now that a buyout may take longer than expected, day traders and speculators alike seem to be heading for the exits. As of 2:37 p.m. EDT, shares were down 9.3%.

So what

Madrigal's stock gained a jaw-dropping 1,800% over the past 12 months, thanks to MGL-3196's strong midstage results in NASH and the potential for a quick buyout offer at a hefty premium. With the company set to take a go-it-alone approach regarding MGL-3196's future development, however, this red-hot biotech stock may cool off in a big way going forward.

Madrigal's shares have already shed a whopping 21% of their value since announcing MGL-3196's top-line results roughly two months ago, and this downward trend appears to be accelerating based on today's action.

Now what

The fact that Madrigal's management is playing hardball with potential suitors isn't necessarily a bad thing, however. After a recent capital raise, the company has more than enough cash to advance MGL-3196 into a late-stage trial. Madrigal's drug is also largely de-risked from a development standpoint and it should have a distinct competitive advantage over most of the field based on its outstanding phase 2 results. So, if anything, Madrigal's asking price in a buyout scenario may only go up from here.

The take-home point is that Madrigal is firmly in the catbird seat from a negotiating standpoint. There's no reason to take a lowball offer right now simply to assuage speculators and day traders. As such, it might be worthwhile to start building a long-term-oriented position in this top biotech while its shares remain well below their 52-week highs.
https://finance.yahoo.com/news/why-madrigal-pharmaceuticals-stock-getting-183933731.html

LOADING UP SOME MORE!!!

GO MDGL

"PEACE"

[DMOST]

How a little 10-employee pharma company hit a whopping $4.4B market cap

While the company doesn’t even list its name or display its logo on the entrance of the shared office space it occupies in West Conshohocken, Madrigal Pharmaceuticals is anonymous no longer.

The 7-year-old company has experienced a rapid rise in its stock price and market capitalization, which at the start of the week was at $4.4 billion.

That’s billion, with a “b,” for a company with just 10 employees.

In the past year, the company’s stock has soared from $15.50 a share to more than $300, hitting a 52-week high of $325.98 last month. It was trading at $286 at the start of this week.

Fueling the growth is the company’s successful results from midstage clinical testing of its new method for treating nonalcoholic steatohepatitis, or NASH, a liver disease that afflicts 20 million people in the United States.

“We were flying under the radar before,” said Paul Friedman, Madrigal’s CEO. “Now we are a known entity even though we are small because NASH is such a big area right now.”

Madrigal is competing with a growing group of biopharmaceutical companies, large and small, developing potential NASH therapies.

The company does not expect to begin the pivotal phase-III clinical trials — the last hurdle before seeking approval of a new medicine — for its experimental treatment, MDL-3196, until later this year or early 2019. Nevertheless, Madrigal attracted interest as a potential acquisition target.

Friedman said no deals are imminent.

“We have the money, a half-of-a-billion dollars in the bank, and the bandwidth to do the phase-III studies ourselves,” he said. “We are moving ahead in that direction. We also feel we have the responsibility to the people who have invested in the company to listen to incoming interest, and there has been a significant amount of incoming interest. We have talked to companies at a very early stage in relatively informal ways. We’ll see if any of that ever develops.”

Dr. Dina Halegoua-De Marzio, director of Thomas Jefferson University Hospital’s Fatty Liver Center, said about 20 potential treatments for NASH are in various stages of development.

https://www.bizjournals.com/philadelphia/news/2018/07/26/how-a-little-10-employee-pharma-company-hit-a.html?ana=yahoo&yptr=yahoo

GO MDGL

"PEACE"

[DMOST]

Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks

ACCESSWIRE•July 17, 2018

Stock Research Monitor: KTOV, LOXO, and MDGL

LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com presents for assessment Kitov Pharma Ltd (NASDAQ: KTOV), Loxo Oncology Inc. (NASDAQ: LOXO), Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), and Mirati Therapeutics Inc. (NASDAQ: MRTX). These stocks are part of the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. All you have to do is sign up today for this free limited time offer by clicking the link below

Madrigal Pharmaceuticals

West Conshohocken, Pennsylvania headquartered Madrigal Pharmaceuticals Inc.’s stock finished the day 2.94% lower at $288.02 with a total trading volume of 118,219 shares. Shares of the Company have skyrocketed 149.48% in the previous three months and 1,767.83% over the past year. The stock is trading above its 50-day and 200-day moving averages by 27.56% and 129.01%, respectively. Additionally, shares of Madrigal Pharma, which focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, have an RSI of 58.11.
https://finance.yahoo.com/news/breakfast-technical-briefing-mirati-therapeutics-113500105.html

On June 28th, 2018, research firm Raymond James initiated a 'Market Perform' rating on the Company's stock. Register for your free research report on MDGL at:

www.wallstequities.com/registration/?symbol=MDGL

GO MDGL

"PEACE"

[DMOST]

3 Biotech Stocks With Big News Coming in NASH

After Gilead Sciences (NASDAQ: GILD) transformed hepatitis C treatment with drugs offering functional cures, biopharmaceutical research has turned its attention toward another significant cause of liver transplant: nonalcoholic steatohepatitis (NASH).

Drugmakers, including Gilead Sciences, are betting NASH will be the next big megablockbuster indication, but they'll need to prove they can develop safe and effective medications for NASH first. Fortunately, we won't have to wait long for an update on their progress. Over the next 12 months, data will be available in the indication from trials being conducted by Gilead Sciences, Viking Therapeutics (NASDAQ: VKTX), and Intercept Pharmaceuticals (NASDAQ: ICPT).
What's NASH?

NASH is a liver disease that results from consuming a high-calorie diet and living a sedentary lifestyle.
A person pinching fat on their belly through a T-shirt
A person pinching fat on their belly through a T-shirt

IMAGE SOURCE: GETTY IMAGES.

In healthy people, the liver contains less than 5% fat. However, in patients with NASH, fat levels can be much higher than that because of excess calories getting stored in the liver.

As fat levels in the liver increase, inflammation occurs in the liver that results in cell death and repair, and thus scarring or fibrosis. When liver fibrosis becomes widespread, patients are considered to have liver cirrhosis, which puts them at greater risk of liver failure and the need for a liver transplant.

Millions of people have NASH, but many likely are unaware of their condition. NASH is called a "silent" disease because people don't experience symptoms until late in disease progression.
Gilead Sciences takes aim at NASH

Gilead Sciences' hepatitis C drugs have been so successful that its addressable market is declining. As a result, its sales have been sliding. To reignite its revenue, the company's investing heavily to expand into new indications, including NASH.

The company's most advanced NASH drug is selonsertib, which is in phase 3 trials. Selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor that's being studied in patients with advanced fibrosis. Because ASK1 activity leads to cell death, inflammation, and scarring, Gilead Sciences thinks crimping its activity can help reduce fibrosis and stall disease progression.

In midstage studies, fibrosis and liver injury measures improved in patients treated with selonsertib for 24 weeks. Specifically, 43% saw at least a one-stage improvement in fibrosis and 26% saw a reduction in liver fat of 30% or more, as measured by magnetic resonance imaging-based proton density fat fraction (MRI-PDFF).

Gilead Sciences finished enrolling patients in selonsertib's phase 3 study in April, and management expects to unveil data from that trial early in 2019. If the late-stage study succeeds, it could allow Gilead Sciences to file selonsertib for Food and Drug Administration (FDA) approval.

A good performance might also bode well for combination studies that are evaluating selonsertib's use alongside either GS-0976 or GS-9674. GS-0976 is an acetyl-CoA carboxylase (ACC) inhibitor that aims to crimp the formation of fat, while GS-9674 is a selective, nonsteroidal farnesoid X receptor (FXR) agonist that could help the body break down more fat.
Viking Therapeutics' midstage study nears its end

Viking Therapeutics isn't in phase 3 trials yet, but data from a phase 2 trial of its NASH candidate, VK2809, will be reported before the end of 2018.

VK2809 is a thyroid hormone receptor beta (TRB) agonist that selectively targets fat in liver tissue and thyroid beta receptors in the liver that modulate cholesterol, triglycerides, and bile acid metabolism. Its selective targeting may boost metabolism and reduce fat buildup in the liver without impacting the cardiovascular system.

They could be onto something. Recently, NASH competitor Madrigal Pharmaceuticals (NASDAQ: MDGL) reported positive data from a phase 2 trial of MGL-3196, a drug with the same mechanism of action as VK2809.

In Madrigal's midstage study, 56% of patients saw a two point or greater improvement in NAFLD Activity Score, a measure of the accumulation of fat in the liver, liver cell swelling, and inflammation. Also, 37% of patients had a 30% or greater reduction in liver fat as measured by MRI-PDFF, and NASH resolution on biopsy at week 36 outperformed placebo. When Madrigal announced its data, management said it thinks it might be able to resolve NASH in up to 40% of patients in as little as nine months.

If Viking Therapeutics delivers similarly strong data, particularly on NASH resolution, then it could end up in a foot race with Madrigal Pharmaceuticals, which plans to talk soon with the FDA about the design of a phase 3 study.
Intercept attempts to expand Ocaliva's label to NASH

Intercept's Ocaliva is already FDA-approved for use in primary biliary cholangitis (PBC), but a much larger opportunity could be unlocked if Ocaliva's phase 3 NASH trial is a success. Ocaliva is a semisynthetic bile acid analogue FXR agonist, so its goal is like that of GS-9674, the FXR agonist that Gilead Sciences is evaluating in its combination trials with selonsertib.

Intercept is on track to report interim data in the first half of 2019 that could support an FDA filing to expand Ocaliva's label to include NASH, as soon as late next year. The approval in PBC offers support to Ocaliva's mechanism of action. However, data in NASH is arguably mixed and there are safety concerns to consider.

In 2014, independent monitors halted Ocaliva's phase 2b Flint NASH study early for efficacy when 45% of patients saw a two-point improvement in NAFLD Activity Score and 35% of patients achieved a one-stage or better improvement in fibrosis.

However, those results weren't duplicated in a separate phase 2 study in Japan. In the Japanese study, only the 40mg dose showed a slight statistical significance to placebo in delivering a two-point or greater NAS improvement. The 0.0496 p-value was only fractionally below the 0.05 level associated with statistical significance. In February 2018, the company that owned the rights to market Ocaliva in Japan returned those rights to Intercept.

Intercept says the Japan study was underpowered for efficacy, though, and if it's right, then its soon-to-finish phase 3 study could read more like the successful Flint study than the Japanese study.

As for Ocaliva's safety, the FDA added a warning to its label earlier this year to emphasize risks associated with incorrect dosing in patients with NASH and Child-Pugh Class B or C scores -- decompensated cirrhosis. The label change was warranted after some Ocaliva patients experienced liver decomposition or failure.

According to Intercept, only 2% to 3% of PBC patients fall into the "warning" patient population, but we'll still want to see if Ocaliva's sales growth slows in the coming quarters. In the first quarter, sales were $35.2 million, and in 2018, guidance is for sales of over $170 million.
The details will matter

NASH drug developers are including a lot of data in their study results. However, the FDA's approvable endpoints for NASH drugs are NASH resolution or fibrosis improvement, so investors might want to downplay results involving other measures.

It remains to be seen how these companies will outmaneuver each other or differentiate their drugs. However, the size of this market could support multiple players, particularly if combination approaches involving different mechanisms of action become standard care.

Of the stocks discussed here, Gilead Sciences is the least risky bet. The company generates significant revenue from other indications, so it's insulated against trial failure. Intercept Pharmaceuticals is a bit more risky because Ocaliva is its only approved drug, and safety concerns raise questions about future sales growth.

Finally, Viking Therapeutics is the riskiest because it's a clinical-stage company without any product sales. If Viking Therapeutics' data trails Madrigal's, or its trial fails, then shares could drop significantly. Alternatively, a trial win could cause a big run-up in its shares. Because of the binary nature of its upcoming results, only risk-tolerant investors should consider owning Viking
https://finance.yahoo.com/news/3-biotech-stocks-big-news-111600906.html

GO MDGL

[DMOST]

Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along

Of note:

Another example of a second quarter SBIO star is Madrigal Pharmaceuticals (NASDAQ:MDGL). The stock saw some profit-taking in late June, but that is to be expected when a stock enters the final trading day of a month with an intra-month gain of over 150%.

In a single trading day in early June, Madrigal cobbled together the bulk of its monthly gains, more than doubling after revealing positive Phase II clinical trial results for its treatment of nonalcoholic steatohepatitis, or NASH.

The stock rallied later in the month on news Madrigal may be exploring a sale, a logical move given the potentially lucrative nature of the NASH market and the desire for large-cap biotechnology and pharmaceuticals companies to gain easy access to that arena.

Madrigal is 2.65% of SBIO’s weight as of Jun. 28.

https://finance.yahoo.com/news/best-etfs-2018-alps-medical-192323242.html

GO MDGL

"PEACE"

[DMOST]

Madrigal Pharmaceuticals Inc (MDGL)......Buyout offer in the $450-$650 range is coming.

GO MDGL

"PEACE"

IF CAN FEEL IT!!!!!!!!!!!!!

[DMOST]

GO MDGL

"PEACE"

[Millions242]

Thanks a million......

[DMOST]

MDGL.........A quicker and more convenient way to check for inside traders.

EASY!!!!!!!!!!!


https://www.finviz.com/insidertrading.ashx?or=-10&tv=100000&tc=7&o=-transactionValue


GO MDGL

"PEACE"



Nothing has changed

[DMOST]

Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

What's the next massive multibillion-dollar market for the biopharmaceutical industry? Put an increasingly prevalent liver disease high on the list.

Some analysts predict that the market for treatments of nonalcoholic steatohepatitis (NASH) could be between $20 billion and $35 billion. The progressive fatty liver disease is expected to become the leading cause of liver transplants by 2020. And there's currently no approved treatment for NASH, so the market is wide open.

With such a huge amount of money on the line, quite a few drugmakers are developing NASH drugs. We'll probably soon see acquisitions activity heat up. I think Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) are highly likely to be gobbled up in the not-too-distant future. My hunch is that Bristol-Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) could be among the potential buyers.
Hand holding marker with drawing of big fish with mouth open next to several small fish with question marks around them
Hand holding marker with drawing of big fish with mouth open next to several small fish with question marks around them

Image source: Getty Images.
Two top targets

Madrigal Pharmaceuticals is practically a no-brainer to rank as one of the most likely acquisition candidates. The company is reportedly considering a sale after catching the eyes of several larger drugmakers, according to Bloomberg.

I'm not surprised at all that Madrigal is contemplating cashing in. In January, I listed the company as one of the top three small biotechs that "big drugmakers are probably drooling over." The drool that I was imagining stemmed from Madrigal's very encouraging phase 2 results reported in December 2017 for lead candidate MGL-3196.

Since then, the news has only gotten better for Madrigal. The company's initial results from the phase 2 study were after 12 weeks of treatment. Madrigal announced a few weeks ago updated results after 36 weeks of treatment. The new data were at least as impressive as the company's earlier report.

One company was probably nearly as pleased with those phase 2 results as Madrigal was -- Viking Therapeutics. Like Madrigal, Viking's lead candidate targets treatment of NASH. Viking's drug, VK2809, uses the same mechanism of action as Madrigal's MGL-3196. Positive results for MGL-3196 should bode well for Viking's chances with VK2809.

Viking is a little behind Madrigal, though. Madrigal is already looking to advance MGL-3196 to a pivotal phase 3 clinical trial. Viking expects to report phase 2 results for VK2809 sometime in the second half of 2018.
Lots of potential suitors

Which big drugmakers could be interested in acquiring Madrigal or Viking? You could probably throw a dart at a list of the biggest biopharmaceutical companies and land on a potential suitor.

I think the odds of either Bristol-Myers Squibb (BMS) or Pfizer making a bid for either of the two smaller biotechs are pretty high. Both companies confirmed to Reuters in April that they're interested in acquisitions in the NASH space.

BMS has four pipeline candidates targeting fibrotic diseases. Three of those experimental drugs are in phase 2 clinical trials while one is in phase 1 development. The most advanced of these candidates is PEG-FGF21, also referred to as BMS-986036. However, the phase 2 results for the drug weren't nearly as positive as Madrigal's results for MGL-3196. I have no doubt that BMS would love to have MGL-3196 in its quiver.
STORY CONTINUES
https://finance.yahoo.com/news/cash-nash-2-top-biotech-183100427.html

GO MDGL

"PEACE"

[Imperial Whazoo]

Thanx man.... It really helps when I ask a simple question and someone is actually gracious in reply, LOL.

IW

[Millions242]

Here's the link for MDGL www.gurufocus.com
You will need to register to see MDGL data and information

[Millions242]

Lots of inside selling from executives. They sold thousands of stocks to make millions. I'm going to post the link later.

[DMOST]

Major Pharmaceuticals Scare Off Short Sellers
https://247wallst.com/healthcare-business/2018/06/12/major-pharmaceuticals-scare-off-short-sellers/

GO MDGL

"PEACE"

Still in and Banking

[DMOST]

Sure,

It's what's systematically happens when these things occur....Nothing wrong, with it. Profits are profits.

But, fear not, the long game / gains continue.

GO MDGL

"PEACE"



Still in banking

[DMOST]

A previous post has the link....(see below)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141515659

GO MDGL

"PEACE"

[TheFinalCD]

good call...

Message in reply to:

Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
https://finance.yahoo.com/news/madrigal-pharmaceuticals-announces-proposed-public-201048593.html

So we are looking at approximately 1m commons to the float? to be followed by a host of form 4's from "insiders" banking?

Had to happen, as the potential riches, profits and money's are looking very attractive to the holders.

Yet still,

MDGL is only a third of the way through its rise, if testing remains positive and an FDA approval chimes in the end............Not to mention any possible buy up / buy out along the way.

WE WILL SEE

GO MDGL

"PEACE"

A Shorts Breather...Take it!

[Imperial Whazoo]

Well, I looked through all my news links to see whether there was something causing the move, but I could not find that info. Do you mind posting whatever link you have that made that info known because my search for something of that kind drew a blank.

That said, I think that, as a day trader, I'd perish rather quickly if I did not rely on the rule that "You trade what you see", so when this thin charged up in that massive 1 minute move, and I aw no corresponding sell down (people taking profits), it was a classic example of this rule.... trade what you see.

So, again, where did you find the info that there are buy-out rumors?

TIA

Imperial Whazoo

[DMOST]

....And of course the rumors of a buy out, has it all looking good.

GO MDGL

"PEACE"

[DMOST]

Madrigal Pharma Is Exploring Sale After Receiving Takeover Interest
[Bloomberg]
Bloomberg•June 13, 2018

Madrigal Pharmaceuticals Inc., with just nine employees and a market value of about $4.3 billion, is exploring a sale after receiving takeover interest from other drugmakers eyeing treatments for a liver disease linked to obesity, people familiar with the matter said. The deliberations are at an early stage and Madrigal may opt to continue operations on its own, they said. Representatives for Madrigal declined to comment, while Centerview didn’t immediately respond to calls.
Continue Reading
https://finance.yahoo.com/m/08254a1a-e253-3429-a7cf-23d4425b8ba5/madrigal.html

GO MDGL

"PEACE"

[Imperial Whazoo]

Let me join in and say that I day trade it and there was just a major buy that renders a rather firm opinion of the value in the offering. Since the major move up in a single minute was on excellent volume that was not mirrored, as of yet, by corresponding profit taking, it looks to me like all the short artists just got their heads handed to them by a big player who knows how to force the shorter to sell by stepping into this stock in a big, quick buy.

On a 3 minute chart, the buy was 241K shares in 3 minutes on a price of $273.45 to $300.00 There was no corresponding crash of profit takers. Thats why I see this as a big player taking out the "all-too-self-assured" short artist as the low hanging fruit that they were. And having forced all those shorters to cover their shorts that way, and given that there is no corresponding crash back down, this thing looks to have a toe hold, at the very least, at the level just below the offering price. As far as the chart itself goes, it looks to me like the market has voted on whether $305 was too high a price for the offering, and they have registered their opinion as a very affirming "YOU BETCHA" in favor of (in support of) that $305 offering price as being supportable.

I mean, lookit folks..... the volume was 241K at a approx $286.5 average price of the 3 minutes of buying... thats $69 million value of the trade that happened in that 3 minute span. Thats huge, even for this stock & if the short artist that have dominated the posts on this board are representative of the market prior to that 3 minute move, then the fact that this did not crash after the move is very, very instructive.

JMHO, but thats how I see it.

Imperial Whazoo

[DMOST]

True. MDGL Has been for me also, as I was in when it took sail for the win.

Made a "MINT"...a government, more than a few Salmon P. Chase's and plan on making some more. As the effects of this offering finally fades, the underwriters finish their trades, and later with news it will move up again while leaving us all to be amazed.

WE WILL SEE

'peace'

[T695]

I think a 10-15% drop is very possible tomorrow

[T695]

This ticker is a traders dream... long and short, I just like the volatility

[DMOST]

MARKED!...........as just another short opinion, wishing for the obvious. With the RSI on high, and no where to fly with the offering price as a ceiling...............May be not kill, but prove a brief feeling of ill. May be, but remember, it has been "Institutionalized".

THERE WILL BE SOME SUPPORT.........KILL, I DON'T THINK SO.

From $108 to $330 in the space of a week, now with an offering. Ya, some pull back and reset is normal..........Get it while it last.

"peace"

It held up pretty good today, considering the news.

[T695]

They going to kill this thing tomorrow... mark my word

[DMOST]

MDGL...little viking.........And so it should it the market determines it to be a better valued pick.

But not right now...........As there is a race to see who makes it to the bigger league (FDA approval) firstly, buy out and or buy up.

Score: $285.32 to $9.30...........Favor, well we know....Madrigal Pharmaceuticals Inc

'peace'

[greens12]

MDGL will tank when Wall st. finds out Viking has a safer more effective Lipid drug.

[greens12]

MDGL sinking while viking is going up...Pair trade working well. Viking has a better lipid drug... will see P2 results soon.

[T695]

New daily low coming soon

[DMOST]

MDGL, Is it really?...Don't keep your pole in that MDGL pond to long.

My Pair trade is working. Short MDGL , Long Viking
'greens12'

You might end up shorting in your shorts.

Viking isn't creating any real noise right now either, and like looking in a MDGL mirror, the reflection you see is it looking back at cha.

Just remember, the crisis is only temporary.

"PEACE"

[greens12]

My Pair trade is working. Short MDGL , Long Viking

[T695]

Or maybe $240

[T695]

$270 seem like a good spot to cover

[DMOST]

Not quite that low, it now seems........Initially $305 a share.

Madrigal Pharmaceuticals Prices Public Offering of Common Stock

Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the pricing of an underwritten registered public offering of 1,347,232 shares of its common stock at a public offering price of $305.00 per share. In the offering, Madrigal will issue and sell 983,607 shares and existing stockholders of the company, including certain of its executive officers and directors and affiliates thereof will sell 363,625 shares. The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $300 million. Madrigal will not receive any proceeds from the sale of the shares by the selling stockholders. Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 202,084 shares of common stock from the company.
https://finance.yahoo.com/news/madrigal-pharmaceuticals-prices-public-offering-031422899.html

It will test the strength and the positive sentiment, towards the stock, going forward, offering an initial win and a chance to cover and profit for shorts.

Many fully expect a temporary drop lower. But $150 a share, would be a "HUGE GIFT" and a no-brainier, for any looking for a second chance......It want happen at that price.

Meanwhile, vktx, will see a similar and on ratio, an equal decline possibly more as they aren't as far along in testing as MDGL........There move, so far, has been because of the positive news and sentiment, surround MDGL

WE WILL SEE if its able to last, are continue to move in Sympathy, with the awareness of MDGL.

Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal
https://finance.yahoo.com/news/maxim-explains-viking-therapeutics-sympathy-201012646.html

"PEACE"

[greens12]

will drop to 150.00 range with upcoming dilution. Shorts will be taking advantage .

[greens12]

The perfect Pair Trade short MDGL which is overbought and buy Viking which is trading 8X less in Value but has a better lipid drug and pipeline only 6 months behind madrigal's and hugely undervalued compared to MDGL.

[DMOST]

Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
https://finance.yahoo.com/news/madrigal-pharmaceuticals-announces-proposed-public-201048593.html

So we are looking at approximately 1m commons to the float? to be followed by a host of form 4's from "insiders" banking?

Had to happen, as the potential riches, profits and money's are looking very attractive to the holders.

Yet still,

MDGL is only a third of the way through its rise, if testing remains positive and an FDA approval chimes in the end............Not to mention any possible buy up / buy out along the way.

WE WILL SEE

GO MDGL

"PEACE"

A Shorts Breather...Take it!

[T695]

BAM there’s there offering lol

[T695]

Will this thing run like SAGE lol
Watching

[investor86]

Thanks.

[T695]

TD